France's NASH contender Genfit leaps onto Nasdaq with $135M IPO
As it gears up for the late-stage readout of its lead experimental NASH drug, France’s Genfit is vaulting onto the Nasdaq on Wednesday with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
